Plasma cell-free DNA in patients with acute promyelocytic leukaemia treated with arsenic trioxide
Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · 2024
DOI: 10.1177/00045632231216596 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical Biochemistry: International Journal of Laboratory Medicine, 2024. Verfasst von Junko Fujihara und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Legal Medicine, Shimane University Faculty of Medicine, Izumo, Japan. Hauptthemen laut MEDLINE: Arsenic Trioxide, Leukemia, Promyelocytic, Acute, Cell-Free Nucleic Acids. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research.
Abstract (Originalsprache)
Background
Cell-free DNA (cfDNA) is free DNA found in circulating blood that originates from apoptosis or necrosis, and elevated cfDNA concentrations have been reported in cancers and other diseases.
Methods
In this study, the concentrations and fragment distributions of plasma cfDNA were preliminary investigated in elderly ( n = 1) and paediatric ( n = 1) patients with acute promyelocytic leukaemia (APL) treated with arsenic trioxide (ATO).
Results
A slight increase in cfDNA concentrations was observed in the APL patients compared with healthy controls. The change in plasma cfDNA concentrations corresponded to the change in plasma arsenic concentrations during ATO treatment. The fragment distribution pattern did not differ before and during treatment. Three ladder fragments were observed in part of the cfDNA in the second consolidation therapy in an elderly APL patient and the first consolidation therapy of a paediatric APL patient, while two fragments were observed in all other treatment periods. Moreover, APL-related gene mutations were successfully genotyped from plasma cfDNA by using polymerase chain reaction-based methods and these results are consistent with those from leukocytes.
Conclusion
This study is the first to report the concentrations and fragment patterns of cfDNA from APL patients treated with ATO. The results suggested that plasma cfDNA concentration in APL patients increased with ATO treatment and that cfDNA is released mainly via neutrophil extracellular traps (and/or necrosis) in addition to apoptosis. To confirm whether cfDNA concentrations and fragment patterns can be used as a biomarker for APL treated with ATO, further accumulative data are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Legal Medicine, Shimane University Faculty of Medicine, Izumo, Japan.
- Shimane Institute for Industrial Technology, Matsue, Japan.
ORCID-Profile: Junko Fujihara, Naoki Nishimoto
Förderung
- Japan Society for the Promotion of Science
- Grant-in-Aid for Scientific Research
Zitieren
APA
Fujihara, J., Nishimoto, N., & Takeshita, H. (2024). Plasma cell-free DNA in patients with acute promyelocytic leukaemia treated with arsenic trioxide. Annals of Clinical Biochemistry: International Journal of Laboratory Medicine. https://doi.org/10.1177/00045632231216596
Vancouver
Fujihara J, Nishimoto N, Takeshita H. Plasma cell-free DNA in patients with acute promyelocytic leukaemia treated with arsenic trioxide. Annals of Clinical Biochemistry: International Journal of Laboratory Medicine. 2024. doi:10.1177/00045632231216596
BibTeX
@article{Fujihara2024,
author = {Fujihara, Junko and Nishimoto, Naoki and Takeshita, Haruo},
title = {Plasma cell-free DNA in patients with acute promyelocytic leukaemia treated with arsenic trioxide},
journal = {Annals of Clinical Biochemistry: International Journal of Laboratory Medicine},
year = {2024},
doi = {10.1177/00045632231216596}
}
EUVIMED